Stock CRBP CORBUS PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Corbus Pharmaceuticals Holdings, Inc.

Equities

CRBP

US21833P3010

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
45.02 USD +8.80% Intraday chart for Corbus Pharmaceuticals Holdings, Inc. +0.04% +645.36%
May. 13 RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target MT
May. 08 Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating MT

Evolution of the average Target Price on Corbus Pharmaceuticals Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

670786c276df.qzL-Lrbektlu52yFCt-QfIQc9S6tuhQ_23cns2qQzQc.zkSRQ_mY_I0qrR3VULzDOc91tHra-0BSmFpI_g6opm_xd5V35-3dmACSIQ~94d3b9098dc06fe1873e705339a10c7a

Analyst Recommendations on Corbus Pharmaceuticals Holdings, Inc.

RBC Initiates Corbus Pharmaceuticals Holdings at Outperform With Speculative Risk Qualifier, $77 Price Target MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $60 From $58, Maintains Outperform Rating MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $58 From $51, Maintains Outperform Rating MT
Jefferies Upgrades Corbus Pharmaceuticals Holdings to Buy From Hold MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $51 From $20, Maintains Outperform Rating MT
Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $20 From $22, Maintains Outperform Rating MT
Oppenheimer Upgrades Corbus Pharmaceuticals to Outperform From Perform, $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
45.02 USD
Average target price
71 USD
Spread / Average Target
+57.71%
High Price Target
77 USD
Spread / Highest target
+71.04%
Low Price Target
60 USD
Spread / Lowest Target
+33.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corbus Pharmaceuticals Holdings, Inc.

RBC Capital Markets
Oppenheimer
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRBP Stock
  4. Consensus Corbus Pharmaceuticals Holdings, Inc.